Clinical trials: Meningococcal
Meningitis, Meningococcal
Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults
The purpose of this study is to evaluate the safety of an investigational meningococcal B rLP2086 vaccine in adults and to obtain blood samples from immunized subjects for use in assay development.
- Trial name
- NCT00780806
- Testing
- meningococcal B rLP2086 vaccine candidate, Blood draw
- Where
- 3 sites in Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Serogroup B Meningococcal Disease
MenPF-1 - A New Vaccine Against Meningococcal Disease
In this study the investigators are testing a new vaccine against Neisseria meningitidis, the leading infective cause of childhood death in the UK.
- Trial name
- NCT01640652
- Testing
- MenPF-1.
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Meningitis, Meningococcal
Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds
Out of the 13 identified serogroups of Neisseria meningitidis (Nm) the six serogroups (A, B, C, W, Y and X) are responsible for majority of infections.
- Trial name
- NCT03295318
- Testing
- Non-adjuvanted study formulation NmCV-5, Adjuvanted study formulation NmCV-5, Menactra
- Where
- Mali
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Meningococcal Disease
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.
The purpose of the study was to assess the immunogenicity and safety of two doses of Novartis Meningococcal B Recombinant (rMenB+OMV NZ) vaccine administered one month apart (0, 1 month schedule) in Korean adolescents aged…
- Trial name
- NCT01973218
- Testing
- Meningococcal B Recombinant vaccine rMenB+OMV NZ, Meningococcal ACWY-CRM conjugate vaccine
- Where
- 7 sites in South Korea
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Infections
Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease
An unusual increase in cases of invasive meningococcal infection between late 2022 and early 2023. These cases sometimes had atypical presentations (large numbers of bacteremias without meningitis).
- Trial name
- CARACIIM (NCT05981599)
- Testing
- There is no intervention
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Poitiers University Hospital
Meningococcal Meningitis, Serogroup B, Transgender Persons
Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons
Sexual differences are a well-established source of biological variation in immune system functioning, with men often displaying lower adaptive immune responses (e.g.
- Conditions
- Meningococcal Meningitis, Serogroup B, Transgender Persons, Sex Differences in Immune Response, Vaccination
- Trial name
- Vaxxygender (NCT06832514)
- Testing
- Serogroup B meningococal vaccine
- Where
- Belgium
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University Ghent
Healthy
Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Children
Haemophilus influenzae is an important pathogen which can cause primary infection and respiratory viral infection in infants and leaded to secondary infections.
- Trial name
- NCT01406509
- Testing
- 0.5ml/dose for a person
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Infection, Meningococcal
Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old
Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, X, and Y)-CRM197 Conjugate vaccine
- Trial name
- NCT05739292
- Testing
- EuNmCV-5, Menveo
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Gonorrhea, Neisseria Gonorrhea
Metagenomic Analysis of the Pharynx in High Risk Partners
The Neisseria gonorrhoea (NG) epidemic in England is at the highest level in one hundred years of public health records. The World Health Organisation has listed NG as one of the top five bacterial infections globally because of…
- Conditions
- Gonorrhea, Neisseria Gonorrhea, Neisseria Meningitidis, Metagenomic Next Generation Sequencing
- Trial name
- NCT07671014
- Volunteers
- 100 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Meningitis
Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 002
The clinical trial was designed to evaluate the safety and immunogenicity against Group ACYW135 Meningococcal Polysaccharide Vaccine of Hualan administered on subjects 2 years of age and older.
- Trial name
- NCT01661738
- Testing
- Group ACYW135 Meningococcal Polysaccharide Vaccine
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Engineering, Inc.
Meningococcal Infections, Meningococcal Meningitis
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
This study will evaluate the lot to lot consistency, safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine in healthy US adolescents and adults.
- Trial name
- NCT00450437
- Testing
- MenACWY CRM, Meningococcal ACWY Conjugate vaccine
- Where
- 40 sites in United States
- Volunteers
- 3,539 people
- Sponsor
- Novartis Vaccines
Infections, Meningococcal
Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years
GlaxoSmithKline Philippines has submitted a registration file for its Purified Meningococcal Polysaccharide of Serogroup ACWY Vaccine (Mencevax ACWY).
- Trial name
- NCT00290329
- Testing
- Mencevax ACWY
- Where
- 8 sites in Philippines
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hiv, Meningococcal Infections
Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV
MENPI is an investigator-initiated single-centre randomized controlled trial which aims to assess the efficacy and safety of meningococcal and pneumococcal vaccination in adults living with HIV receiving antiretroviral treatment.
- Conditions
- Hiv, Meningococcal Infections, Pneumococcal Infections
- Trial name
- MENPI (NCT04875819)
- Testing
- Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Thomas Benfield
Meningitis
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
The purpose of this observer-blind study is to evaluate the safety, reactogenicity and immunogenicity of Meninggococcal (A,C,Y and W135) Conjugate Vaccine in 2 months to 6 years-old children.
- Trial name
- NCT02003495
- Testing
- MCV-ACYW135 Vaccine Group, MPV-ACYW135 Vaccine Group, MPV-A Vaccine Group
- Where
- China
- Volunteers
- 2,195 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
MENINGOCOCCAL INFECTION
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young children.
- Trial name
- NCT02531698
- Testing
- Bivalent rLP2086 Vaccine, Licensed pediatric hepatits A vaccine, Normal Saline
- Where
- 15 sites in Finland, Poland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Prevention of Meningococcal Infection
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in healthy children
- Trial name
- NCT00311415
- Testing
- Meningococcal C conjugate vaccine
- Where
- 2 sites in Germany, Poland
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Infection
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
- Trial name
- NCT00310635
- Testing
- Meningococcal C conjugate vaccine
- Where
- Germany
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Novartis
Meningococcal Disease, Meningococcal Meningitis
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults
The proposed study will evaluate the safety of the rMenB+OMV NZ in an adult population potentially at risk for meningococcal disease (e.g. lab workers).
- Trial name
- NCT01478347
- Testing
- Recombinant meningococcal B + OMV NZ
- Where
- Italy
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Neisseria Meningitidis, Meningococcal Infections
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
This study will be conducted among adolescents in Saudi Arabia who previously received one dose of A, C, Y, W 135 and at least one dose of A, C meningococcal polysaccharide vaccine.
- Trial name
- NCT00444951
- Testing
- Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine, Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine
- Where
- 7 sites in Saudi Arabia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Meningitis
A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
This is a multicenter, randomized, double-blinded, positive controlled study to evaluate the lot-to-lot consistency, immunogenicity and safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in adults aged 18 to 55…
- Trial name
- NCT06131554
- Testing
- batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4), batch 2 of MCV4, batch 3 of MCV4
- Where
- Indonesia
- Volunteers
- 1,480 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.